TVTX · Company research
Travere Therapeutics, Inc. Common Stock (TVTX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| The CEO exercises options at $8.93 and sells shares in Travere Therapeutics (TVTX). - Stock Titan | The CEO exercises options at $8.93 and sells shares in Travere Therapeutics (TVTX). Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits | TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari Stocktwits | View source ↗ | Stocktwits | Oct 18, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics Stock Price Forecast. Should You Buy TVTX? - StockInvest.us | Travere Therapeutics Stock Price Forecast. Should You Buy TVTX? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history - Yahoo Finance Australia | Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 16, 2026 | neutral | 0 | 0.6 |
| An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX). - Stock Titan | An officer proposes selling 243,735 shares at Travere Therapeutics (TVTX). Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Behavioral Patterns of TVTX and Institutional Flows - Stock Traders Daily | Behavioral Patterns of TVTX and Institutional Flows Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 14, 2026 | neutral | 0 | 0.6 |
| Dow, S&P 500, Nasdaq Futures Gain As Trump Signals Iran Talks Could Resume: Why SNDK, BMNR, ORCL, BE, TVTX Kept Traders On Edge Today - Stocktwits | Dow, S&P 500, Nasdaq Futures Gain As Trump Signals Iran Talks Could Resume: Why SNDK, BMNR, ORCL, BE, TVTX Kept Traders On Edge Today Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits | TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history - Yahoo Finance UK | Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 13, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits | Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics, Inc. (TVTX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Travere Therapeutics, Inc. (TVTX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 12, 2026 | neutral | 0 | 0.6 |
| After two years on a kidney drug, 75% of 12 patients saw urine protein fall to remission levels - Stock Titan | After two years on a kidney drug, 75% of 12 patients saw urine protein fall to remission levels Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Understanding the Setup: (TVTX) and Scalable Risk - Stock Traders Daily | Understanding the Setup: (TVTX) and Scalable Risk Stock Traders Daily | View source ↗ | Stock Traders Daily | Sep 24, 2026 | neutral | 0 | 0.6 |
| A kidney drug could get U.S. patent protection for some uses into October 2037. - Stock Titan | A kidney drug could get U.S. patent protection for some uses into October 2037. Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today - Yahoo Finance | Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today Yahoo Finance | View source ↗ | Yahoo Finance | Sep 22, 2026 | neutral | 0 | 0.6 |
| Travere's CEO plans to step down after nearly eight years. A new leader takes over Dec. 1. - Stock Titan | Travere's CEO plans to step down after nearly eight years. A new leader takes over Dec. 1. Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics: Valuation Suggests A Buy (NASDAQ:TVTX) - Seeking Alpha | Travere Therapeutics: Valuation Suggests A Buy (NASDAQ:TVTX) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 19, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics (TVTX) Stock Climbs On FILSPARI Momentum As Losses Deepen - Simply Wall Street | Travere Therapeutics (TVTX) Stock Climbs On FILSPARI Momentum As Losses Deepen Simply Wall Street | View source ↗ | Simply Wall Street | Aug 6, 2026 | neutral | 0 | 0.6 |
| Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On - Benzinga | Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On Benzinga | View source ↗ | Benzinga | Aug 5, 2026 | neutral | 0 | 0.6 |
| TVTX Forecast — Price Target — Prediction for 2027 - TradingView | TVTX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits | TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside Stocktwits | View source ↗ | Stocktwits | Jun 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.